Monteverde & Associates Opens Inquiry Into Forte Biosciences Sale
Shareholders of Forte Biosciences, Inc. are facing a potential buyout as the company navigates a proposed acquisition by argenx BV. With the deal valued at $77.00 per share in cash, legal scrutiny has emerged regarding whether the transaction represents a fair valuation for those holding common stock in the firm.
New York-based Monteverde & Associates PC, a firm noted for its work in securities litigation, has launched an investigation into the terms of the pending merger. Attorney Juan Monteverde, whose firm is headquartered in the Empire State Building, is currently evaluating the circumstances surrounding the deal to determine if investors are being adequately compensated.
Those currently holding FBRX common stock may contact the firm to review the details of the transaction at no cost. The investigation focuses on whether the board of directors fulfilled their fiduciary duties during the negotiation process with argenx BV. Potential claimants are encouraged to reach out to the firm directly for information regarding their legal standing and the specifics of the ongoing review.
Comments (0)
No comments yet. Be the first!